Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for Compass Therapeutics (CMPX) over the last 2 years, with Dec 2024 value amounting to $140.4 million.

  • Compass Therapeutics' Liabilities and Shareholders Equity rose 55.05% to $231.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $619.8 million, marking a year-over-year decrease of 0.48%. This contributed to the annual value of $140.4 million for FY2024, which is 10.50% down from last year.
  • Compass Therapeutics' Liabilities and Shareholders Equity amounted to $140.4 million in FY2024, which was down 10.50% from $156.9 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Liabilities and Shareholders Equity registered a high of $156.9 million during FY2023, and its lowest value of $140.4 million during FY2024.
  • Over the past 2 years, Compass Therapeutics' median Liabilities and Shareholders Equity value was $148.6 million (recorded in 2023), while the average stood at $148.6 million.
  • Data for Compass Therapeutics' Liabilities and Shareholders Equity shows a maximum YoY fell of 10.50% (in 2024) over the last 5 years.
  • Over the past 2 years, Compass Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $156.9 million in 2023, then decreased by 10.50% to $140.4 million in 2024.